Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Pfizer
Femme et Homme Max 99 ans
Pfizer, S.L.U
MAJ Il y a 5 ans
This study investigates the effects of various smoking cessation therapies on people with and without a history of psychiatric conditions
Primary Safety Objectives: 1. To characterize the neuropsychiatric safety profiles of varenicline and bupropion by estimating the differences from placebo in the incidence of the primary neuropsychiat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Pharma GmbH
MAJ Il y a 5 ans
Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 as Second- or Later-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
The primary objective of this study is to determine the activity of AG-013736 in advanced non-small cell lung cancer as measured by the overall response rate, complete response (CR) and partial respon...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Limited
MAJ Il y a 5 ans
RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF THE EFFICACY, TOLERABILITY AND SAFETY OF VALDECOXIB (BEXTRA®)10 MG OD VS. DICLOFENAC SODIUM 50 MG TDS FOR 6 WEEKS IN SUBJECTS WITH OSTEOARTHRITIS OF THE KNEE
The primary objective of this study is to demonstrate that valdecoxib 10 mg administered once daily for 6 weeks is not inferior to diclofenac sodium 50 mg administered three times daily for a total da...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Pfizer AB
MAJ Il y a 5 ans
EXPLORATORY EVALUATION OF A SEQUENTIAL ADMINISTRATION OF DOCETAXEL AND SU011248 IN WOMEN WITH ADVANCED BREAST CANCER
To characterize the pharmacokinetics of docetaxel and SU011248 (and its metabolite, SU012662) according to the schedule adopted in the trial.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc 235 East 42nd Street, New York, NY10017
MAJ Il y a 5 ans
A study in patients with Non-Hodgkin Lymphoma (NHL) to evaluate safety and effectiveness of a new drug combination compared to 2 other drug combinations that have already been studied in clinical trials. This study will include patients who have already received therapy for their NHL (but it returned or was not completely cured), and now intense chemotherapy is not the best treatment option due to reasons like health or age. The types of NHL include Diffuse Large B-Cell Lymphoma and others
To evaluate efficacy as measured by overall survival (OS), with a goal of demonstrating the superiority of inotuzumab ozogamicin when administered in combination with rituximab, compared with an act...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer, S. A
MAJ Il y a 5 ans
A TREATMENT PROTOCOL FOR PATIENTS CONTINUING FROM A PRIOR SU011248 PROTOCOL Protocolo de continuación de tratamiento para pacientes provenientes de un protocolo previo con SU011248
The primary objective is to provide access to SU011248 treatment for patients who have partecipated in other SU011248 protocol and have the potentila to derive clincial benefit from SU011248 tretamen...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Pfizer Inc
MAJ Il y a 5 ans
A PHASE 2 STUDY OF THE EFFICACY AND SAFETY OF SU-014813 IN PATIENTS WITH METASTATIC BREAST CANCER
To determine the antitumor efficacy of single agent SU-014813 at a dose of 100 mg orally once daily in patients with metastatic breast cancer
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Pfizer (Australia) - competitive cardiovascular lipid grant 2003 and internal departmental fund
MAJ Il y a 5 ans
The effects of medical therapy on insulin resistance and the cardiovascular system in PolyCystic Ovarian Syndrome
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc.235 East 42nd Street, New York, NY 10017
MAJ Il y a 5 ans
Study with investigational drug PF-06463922 in patients with a specific type of advanced lung cancer Estudio con fármaco en investigación PF-06463922 en pacientes con un tipo específico de cáncer de pulmón
This study has separate primary objectives for the two study portions: Phase 1 and Phase 2. Phase 1 study portion: To assess safety and tolerability of PF-06463922 as a single agent at increasing dose...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Pfizer Inc
MAJ Il y a 5 ans
Randomized, Double-Blind, Placebo-Controlled Trial of etanercept plus methotrexate in monoclonal antibody (mAb) anti-TNF failure
To compare the efficacy of etanercept to placebo in inadequate responders to infliximab or adalimumab plus methotrexate (MTX) in all subjects and in subjects who are anti-drug antibody positive (ADA+)...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
17
18
19
20
21
22
23
24
25
26
Suivant